Crizotinib

克唑替尼

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameCrizotinib
Drug Alias NameCrizotinibum克里唑蒂尼克卓替尼克佐替尼Xalkori +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsMacrophage-stimulating protein receptor inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors +[4] 
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROSMacrophage-stimulating protein receptor +[4] 
Therapy Area/IndicationsUveal melanomaSolid tumoursGranuloma, Plasma Cell +[22] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2011/08/26
Country/TerritoryBelgiumBulgariaCanada +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer LtdUniversity Of Milano BicoccaPfizer Inc +[8] 
Inactive CompaniesWake Forest University Health SciencesPfizer Manufacturing Deutschland GmbhColumbia University +[9] 
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[11] 
Inactive IndicationsUveal melanomaGranuloma, Plasma CellRenal Insufficiency +[11] 

Other Information

ATC CodeL01ED01
Related LinksWikipediaDrugBankKEGG